Better leukemia-free survival with allogeneic than with autologous hct in aml patients with isolated trisomy 8: a study from the alwp of the ebmt - Université de Lille Accéder directement au contenu
Article Dans Une Revue Bone Marrow Transplantation Année : 2021

Better leukemia-free survival with allogeneic than with autologous hct in aml patients with isolated trisomy 8: a study from the alwp of the ebmt

Frederic Baron
Myriam Labopin
  • Fonction : Auteur
Didier Blaise
  • Fonction : Auteur
Maija Itala-Remes
  • Fonction : Auteur
Edouard Forcade
  • Fonction : Auteur
Norbert Claude Gorin
  • Fonction : Auteur
Jordi Esteve
  • Fonction : Auteur
Arnon Nagler
  • Fonction : Auteur
Mohamad Mohty
  • Fonction : Auteur

Résumé

The indication for performing an allogeneic hematopoietic stem cell transplantation (allo-HCT) in patients with isolated trisomy 8 AML in first complete remission (CR) is still debated. Here, we compared outcomes of such patients given either allo-HCT or autologous (auto)-HCT. Inclusion criteria consisted of adult patients with de novo AML, isolated trisomy 8, first HCT between 2000 and 2018, CR1 at transplantation, and either auto-HCT or allo-HCT with a HLA-identical sibling donor (MSD) or a 10/10 HLA-matched unrelated donor (UD 10/10). A total of 401 patients met the inclusion criteria. They underwent an auto-HCT (n = 81), allo-HCT with a MSD (n = 186) or allo-HCT with a 10/10 UD (n = 134). At 3 years, relapse incidence, nonrelapse mortality and leukemia-free survival (LFS) were 59%, 5%, and 37%, respectively, in auto-HCT recipients; 31% (P < 0.001), 14% (P = 0.04), and 55% (P = 0.033), respectively, in MSD recipients and 29% (P < 0.001), 13% (P = 0.15), and 59% (P = 0.03), respectively, in UD 10/10 recipients. In multivariate analysis, in comparison to auto-HCT, MSD and UD 10/10 were associated with a lower risk of relapse (HR = 0.47, P < 0.001 and HR = 0.40, P < 0.001, respectively) translating to better LFS (HR = 0.69, P = 0.04 and HR = 0.60, P = 0.03, respectively). There was also a similar trend for overall survival (HR = 0.73, P = 0.12 and HR = 0.65, P = 0.08).

Dates et versions

hal-04403273 , version 1 (18-01-2024)

Identifiants

Citer

Frederic Baron, Myriam Labopin, Didier Blaise, Maija Itala-Remes, Gerard Socie, et al.. Better leukemia-free survival with allogeneic than with autologous hct in aml patients with isolated trisomy 8: a study from the alwp of the ebmt. Bone Marrow Transplantation, 2021, Bone Marrow Transplantation, 56, pp.461-469. ⟨10.1038/s41409-020-01051-6⟩. ⟨hal-04403273⟩
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More